Dyne Therapeutics, Inc. DYN Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dyne Therapeutics, Inc.'s net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dyne Therapeutics, Inc.'s net unrealized gains (losses) on securities still held?
- Dyne Therapeutics, Inc. (DYN) reported net unrealized gains (losses) on securities still held of -$612K in Q1 2026.
- How has Dyne Therapeutics, Inc.'s net unrealized gains (losses) on securities still held changed year-over-year?
- Dyne Therapeutics, Inc.'s net unrealized gains (losses) on securities still held decreased by 360.4% year-over-year, from $235K to -$612K.
- What is the long-term trend for Dyne Therapeutics, Inc.'s net unrealized gains (losses) on securities still held?
- Over 2 years (2021 to 2025), Dyne Therapeutics, Inc.'s net unrealized gains (losses) on securities still held has grown at a 42.3% compound annual growth rate (CAGR), from -$242K to $490K.
- What does net unrealized gains (losses) on securities still held mean?
- This metric reflects the change in the fair value of investment securities held by the company that have not yet been sold. These gains or losses are recorded in other comprehensive income rather than net income, as they are considered unrealized. Monitoring this figure helps investors assess the volatility and performance of the company's investment portfolio outside of core operating activities.